Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 May 18:5:10227.
doi: 10.1038/srep10227.

Serum IGFBP7 levels associate with insulin resistance and the risk of metabolic syndrome in a Chinese population

Affiliations

Serum IGFBP7 levels associate with insulin resistance and the risk of metabolic syndrome in a Chinese population

Yi Liu et al. Sci Rep. .

Abstract

Metabolic syndrome (MetS), one of the major public health concerns, is regarded as the "common soil" of incidence of common chronic diseases and may increase the risk of type 2 diabetes. The predominant underlying mechanism of MetS is insulin resistance (IR). Additionally, previous studies have indicated that IGFBP7 has high affinity of binding with insulin and might induce IR. The objective of this study was to firstly evaluate the associations of serum IGFBP7 levels with IR and MetS with a relatively large sample and population based design. In a population based MetS case-control study, HOMA-IR was used to evaluate the insulin sensitivity and serum IGFBP7 levels were determined with chemiluminescence-linked immunoassay. As a result, the subjects of MetS and IR had higher serum levels of IGFBP7 than control healthy subjects. High serum IGFBP7 levels increased the risk of MetS and IR. Serum IGFBP7 levels were also found to be significantly correlated with metabolic-associated parameters of Waist-to-hip ratio (WHR), HDL and LDL. These findings suggest that serum IGFBP7 levels are associated with IR and MetS, providing new insight into the mechanism of IR and Mets. IGFBP7 may be a potential interventional target for IR and Mets.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Alberti K. G., Zimmet P., Shaw J. & Group I. D. F. E. T. F. C. The metabolic syndrome–a new worldwide definition. Lancet 366, 1059–1062, doi:10.1016/S0140-6736(05)67402-8 (2005). - DOI - PubMed
    1. Cameron A. J., Zimmet P. Z., Shaw J. E. & Alberti K. G. The metabolic syndrome: in need of a global mission statement. Diabet Med. 26, 306–309, doi:10.1111/j.1464-5491.2009.02681.x (2009). - DOI - PubMed
    1. Simmons R. K. et al. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia 53, 600–605, doi:10.1007/s00125-009-1620-4 (2010). - DOI - PubMed
    1. Hunt K. J., Williams K., Hazuda H. P., Stern M. P. & Haffner S. M. The metabolic syndrome and the impact of diabetes on coronary heart disease mortality in women and men: the San Antonio Heart Study. Ann. Epidemiol. 17, 870–877, doi:10.1016/j.annepidem.2007.05.012 (2007). - DOI - PMC - PubMed
    1. Klein B. E., Klein R. & Lee K. E. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care 25, 1790–1794 (2002). - PubMed

Publication types

Substances